Clinical trial
Clinical Study of R744 to Hemodialysis Patients
NCT00491868 · Chugai Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00491868 |
|---|---|
| Title | Clinical Study of R744 to Hemodialysis Patients |
| Official title | Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients ( Phase III, Double Blind Study in Comparison With Epoetin Beta). |
| Lead sponsor | Chugai Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hemodialysis Patients |
| Intervention type | Drug |
| Interventions | R744, rHuEPO, R744 placebo, rHuEPO placebo |
| Enrollment | 134 |
| Start date | Jun 1, 2007 |
| Primary completion | May 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Jun 26, 2007 |
| Last update posted | Feb 2, 2009 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: